Advanced in Swallowing Difficulty

Sven G. Meuth

Ratzeburger Allee 160, 
Luebeck, SH, DE 
Advanced in Swallowing Difficulty
Ratzeburger Allee 160, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Sven Meuth practices in Luebeck, Germany. Mr. Meuth is rated as an Advanced expert by MediFind in the treatment of Swallowing Difficulty. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Relapsing Multiple Sclerosis (RMS), Tissue Biopsy, and Thrombectomy.

His clinical research consists of co-authoring 636 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Swallowing Difficulty.

Gender
Male

Locations

Ratzeburger Allee 160, Luebeck, SH 23538, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)
A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)
Enrollment Status: Completed
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

636 Total Publications

AhR signaling in skin-resident CD207+ cells is involved in UV-B-induced amelioration of neuroinflammation.
AhR signaling in skin-resident CD207+ cells is involved in UV-B-induced amelioration of neuroinflammation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Meuth's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 87 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile